Nanobody-Based Antivenoms Could Transform Snakebite Treatment, Study Finds in Mice

Overview

Snakebites kill tens of thousands annually and current antivenoms, largely horse-derived, have limitations including batch variability, allergic reactions, and high costs. A new study led by Kartik Sunagar investigates nanobody-based antivenoms that are smaller, thermostable, and producible in microbes. In mice, a five-nanobody cocktail neutralized venoms from several cobra species and provided protection even when delivered after venom exposure.

Key insights

• Nanobodies move quickly through tissues, potentially reaching venom faster than traditional antivenoms.
• A cocktail of five nanobodies targeted toxins across African and Indian cobra venoms, suggesting cross-species applicability.
• In vivo experiments showed all treated mice survived venom exposure, even with a simulated bite scenario closer to clinic arrival times.
• The approach is not universal; additional nanobodies would be needed for kraits and other vipers, and human trials will require safety and manufacturing standards.

Context and the snakebite burden

Snakebites remain a major global health issue, with annual death tolls estimated between 80,000 and 140,000 people and hundreds of thousands suffering disabilities. India bears a large share of this burden, with tens of thousands of deaths each year. Traditional antivenoms have saved countless lives but come with drawbacks: batch-to-batch variability, risk of severe allergic reactions, high production costs, and limited cross-reactivity across snake species. In India, the most common formulations rely on venom pools from the “big four” species, which may not fully neutralize venoms from other local snakes or populations. Against this backdrop, researchers explored whether modern biotechnology could yield a more flexible and broadly protective antivenom strategy.

The nanobody strategy

The study focuses on nanobodies, tiny antibody fragments that retain functional binding specificity but are much smaller than conventional antibodies. Nanobodies can penetrate tissues more rapidly and can be produced in microbes, bypassing some limitations of animal-based antivenom production. The researchers previously developed nanobodies that neutralize venoms from African cobras and mambas and asked whether these could also neutralize Indian cobra venoms due to shared toxin families. In a race against venom diversity, a cocktail of five nanobodies was assembled and tested against venoms from several cobra and king cobra species native to India.

Lab findings: cross-species neutralization

In controlled lab assays, each of the five nanobodies contributed to neutralizing toxins across multiple cobra venoms. Importantly, the combination was effective against Indian cobra venoms even though initial nanobodies were developed using African snake venoms. This cross-species activity is significant because it hints at a shared set of toxins across cobra venoms that can be targeted with a common nanobody toolkit, offering a path toward regionally adaptable, scalable antivenom production.

From the lab to living animals

The cocktail was then evaluated in mice. When venom and nanobodies were administered together, all treated mice survived whereas untreated mice succumbed rapidly to neurotoxicity. The team also simulated a bite scenario where venom was delivered first and nanobodies were infused intravenously after a delay. Impressively, the treatment still saved mice when given 20 minutes after venom administration, and it prevented severe outcomes such as paralysis and breathing failure. These results demonstrate potential real-world utility, where patients often reach clinics after some delay following a snakebite.

Safety, stability, and specificity

Beyond efficacy, the researchers confirmed that the nanobodies did not bind to human proteins, reducing concerns about off-target effects. They also found the nanobodies remained intact at elevated temperatures, a critical feature for distribution in regions with limited cold-chain infrastructure. The study emphasizes that while promising, the work is an early preclinical step and not a direct translation to humans. There are important questions about pharmacokinetics, dosing, and duration of protection, especially in larger animals and humans.

Limitations and next steps

The nanobody cocktail is not a universal antivenom. It did not neutralize venoms from Indian kraits and some vipers, underscoring the need to add region-specific nanobodies to cover the full spectrum of local snakes. The authors outline subsequent steps: confirming safety in humans, determining optimal dosing, scaling production to pharmaceutical standards, and ultimately conducting clinical trials with snakebite patients. They also note that cross-species success in mice does not guarantee identical outcomes in humans, and further research is required to understand duration of protection and performance when treatment is delayed by longer periods after envenomation. The work builds on prior research and suggests that a modular, nanobody-based approach could lead to a more flexible and effective antivenom strategy for snakebite relief on a global scale.

Broader implications and context

If realized in humans, nanobody-based antivenoms could transform snakebite treatment by providing a modular, regionally adaptable library of nanobodies, produced via microbial systems rather than horses, and potentially more thermostable. A concerted effort would be required to translate these findings into clinical practice, including regulatory approvals, manufacturing under pharmaceutical standards, and establishing distribution networks in rural, high-risk settings. The study is part of a broader trend toward biotechnological innovations in toxin neutralization and infectious disease management, aligning with ongoing public-health goals to improve access to safe, effective antivenoms worldwide.

Context and collaboration

The article, authored by Kartik Sunagar and published as part of a Videnskab.dk and The Conversation collaboration, situates these findings within the ongoing conversation about snakebite treatment and global health. The work underscores a potential shift from traditional antivenom production toward newer biotechnologies that could expand access and efficacy in diverse geographic regions.